---
title: "Real-world Use and Reported Harms of BPC-157 and TB-500 for Musculoskeletal Injury"
id: "medrxiv-10-real-world-use-dosing-and-reported-side-effects-of-bpc-157-and-tb-500-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-real-world-use-dosing-and-reported-side-effects-of-bpc-157-and-tb-500-for"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.04.26367022v1?rss=1"
published_at: "2026-11-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Real-world Use and Reported Harms of BPC-157 and TB-500 for Musculoskeletal Injury
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-real-world-use-dosing-and-reported-side-effects-of-bpc-157-and-tb-500-for
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.04.26367022v1?rss=1)
- **Published At:** 2026-11-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analyzed 92,254 Reddit posts and comments from 28,652 users across peptide communities between 2021 and 2026. - The study used a large language model validated against physician review to identify posts describing use of **BPC-157** and **TB-500** for tendon, ligament, and muscle injury. - A total of 5,588 users reported using one or both peptides for a specific musculoskeletal injury, most commonly chronic tendon problems of the shoulder, knee, or elbow. - Only 3.8% of those users described physician involvement in their peptide use; among users who named a source, 90.9% purchased from research-chemical vendors. - Median per-injection **BPC-157** dose was 366 mcg; investigators compared this to a cited rat regimen but the source did not report additional pharmacologic detail beyond the median. - Among new users, reported median **BPC-157** dose rose from 300 mcg in 2024 to 500 mcg in 2025, indicating dose escalation in online practice. - Of users reporting outcomes, 79.3% described improvement; 36.6% of all users also reported participating in physical therapy. - Overall, 27.2% of users described at least one side effect; the most frequent were fatigue, anxiety, anhedonia, and insomnia. - Anhedonia was reported more often among **BPC-157/TB-500** users with side effects (10.2%) than among users of four comparator peptides (1.3% of those with side effects), per the dataset. - The study team concluded that use of these unapproved peptides is largely unsupervised, sourced from the grey market, and administered at rising, self-selected doses without established safety or efficacy. - The preprint notes ethics oversight (IRB waiver) and that raw Reddit data cannot be shared due to platform terms; code and analytic materials are available on request from authors.
## Clinical Analysis & Structured Key Points
Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities | medRxiv Skip to main content Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities Joshua J Cassinat , Claire Callan , Catherine Liggett , Vonda Wright doi: https://doi.org/10.64898/2026.11.04.26367022 Joshua J Cassinat 1 University of Colorado School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: joshua.cassinat{at}cuanschutz.edu Claire Callan 1 University of Colorado School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catherine Liggett 1 University of Colorado School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vonda Wright 2 University of Central Florida College of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Objective: To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. Methods: Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit's peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. Results: In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 mcg per injection) was about 2.7 times the human-equivalent dose of the 10 mcg/kg rat regimen, and among new users it rose from 300 mcg in 2024 to 500 mcg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects). Conclusion: Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Colorado Multiple Institutional Review Board of the University of Colorado Anschutz Medical Campus waived ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data used in this study are publicly available from Reddit.com or are accessible via Arctic Shift. Due to Reddit's Terms of Use, we are unable to share the raw data. All Reddit data in this study were used in accordance with Reddit's Terms of Use. Code, prompts, schemas and annotation guides to reproduce the analyses are available from the corresponding author on reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 06, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities Joshua J Cassinat , Claire Callan , Catherine Liggett , Vonda Wright medRxiv 2026.11.04.26367022; doi: https://doi.org/10.64898/2026.11.04.26367022 Share This Article: Copy Citation Tools Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities Joshua J Cassinat , Claire Callan , Catherine Liggett , Vonda Wright medRxiv 2026.11.04.26367022; doi: https://doi.org/10.64898/2026.11.04.26367022 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (638) Allergy and Immunology (917) Anesthesia (350) Cardiovascular Medicine (5002) Dentistry and Oral Medicine (496) Dermatology (428) Emergency Medicine (676) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1691) Epidemiology (16255) Forensic Medicine (36) Gastroenterology (1241) Genetic and Genomic Medicine (7278) Geriatric Medicine (751) Health Economics (1093) Health Informatics (5286) Health Policy (1467) Health Systems and Quality Improvement (1832) Hematology (599) HIV/AIDS (1381) Infectious Diseases (except HIV/AIDS) (16487) Intensive Care and Critical Care Medicine (1203) Medical Education (700) Medical Ethics (156) Nephrology (752) Neurology (7593) Nursing (377) Nutrition (1129) Obstetrics and Gynecology (1296) Occupational and Environmental Health (1040) Oncology (3744) Ophthalmology (1093) Orthopedics (409) Otolaryngology (465) Pain Medicine (501) Palliative Medicine (143) Pathology (721) Pediatrics (1858) Pharmacology and Therapeutics (755) Primary Care Research (786) Psychiatry and Clinical Psychology (6126) Public and Global Health (9990) Radiology and Imaging (2530) Rehabilitation Medicine and Physical Therapy (1516) Respiratory Medicine (1269) Rheumatology (661) Sexual and Reproductive Health (804) Sports Medicine (596) Surgery (803) Toxicology (109) Transplantation (319) Urology (307)
## Related Clinical Research

- [Sleep quality, anxiety, and glycemic control in adults with type 2 diabetes](https://medichelpline.com/clinical-feed/pubmed-43013710.md) (DOI: 10.1371/journal.pone.0361467)
- [Topiramate target genetics suggest reduced binge-eating risk via CA4 inhibition](https://medichelpline.com/clinical-feed/medrxiv-19-investigating-the-potential-effect-of-topiramate-on-anorexia-nervosa-and-binge.md)
- [Kratom, 7-OH, and MGPI: What clinicians need to know about use, risks, and regulation](https://medichelpline.com/clinical-feed/stat-news-2-most-people-haven-t-heard-of-kratom-what-is-it-and-who-s-using-it.md)
- [Semaglutide and Panic Attacks: FAERS Disproportionality, Notoriety Bias, and Evidence Triangulation](https://medichelpline.com/clinical-feed/pubmed-42946127.md) (DOI: 10.1002/pds.70517)
- [Regulation of Kratom and 7-OH: Experts Call for Action and Debate Solutions](https://medichelpline.com/clinical-feed/stat-news-1-kratom-and-7-oh-should-be-regulated-experts-agree-they-re-split-on-how.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.